International Journal of Cancer Management

Published by: Kowsar

Anti-Proliferative Effects of Piroxicam and Nimesulide on A431 Human Squamous Carcinoma Cell Line

Faezeh Khodaie 1 , Yalda Khazaei-Poul 1 and Taraneh Moini-Zanjani 1 , *
Authors Information
1 Department of Pharmacology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
Article information
  • International Journal of Cancer Management: April 2017, 10 (4); e7565
  • Published Online: April 22, 2017
  • Article Type: Research Article
  • Received: June 15, 2016
  • Accepted: March 8, 2017
  • DOI: 10.5812/ijcm.7565

To Cite: Khodaie F, Khazaei-Poul Y, Moini-Zanjani T. Anti-Proliferative Effects of Piroxicam and Nimesulide on A431 Human Squamous Carcinoma Cell Line, Int J Cancer Manag. 2017 ; 10(4):e7565. doi: 10.5812/ijcm.7565.

Copyright © 2017, International Journal of Cancer Management. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Karia PS, Han J, Schmults CD. Cutaneous squamous cell carcinoma: estimated incidence of disease, nodal metastasis, and deaths from disease in the United States, 2012. J Am Acad Dermatol. 2013; 68(6): 957-66[DOI][PubMed]
  • 2. Christenson LJ, Borrowman TA, Vachon CM, Tollefson MM, Otley CC, Weaver AL, et al. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA. 2005; 294(6): 681-90[DOI][PubMed]
  • 3. Basra MK, Shahrukh M. Burden of skin diseases. Expert Rev Pharmacoecon Outcomes Res. 2009; 9(3): 271-83[DOI][PubMed]
  • 4. Rudnick EW, Thareja S, Cherpelis B. Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies. Int J Dermatol. 2016; 55(3): 249-58[DOI][PubMed]
  • 5. Soura E, Chasapi V, Stratigos AJ. Pharmacologic treatment options for advanced epithelial skin cancer. Expert Opin Pharmacother. 2015; 16(10): 1479-93[DOI][PubMed]
  • 6. Peiris-Pages M, Sotgia F, Lisanti MP. Doxycycline and therapeutic targeting of the DNA damage response in cancer cells: old drug, new purpose. Oncoscience. 2015; 2(8): 696-9[DOI][PubMed]
  • 7. Yadav V, Varshney P, Sultana S, Yadav J, Saini N. Moxifloxacin and ciprofloxacin induces S-phase arrest and augments apoptotic effects of cisplatin in human pancreatic cancer cells via ERK activation. BMC Cancer. 2015; 15: 581[DOI][PubMed]
  • 8. dela Cruz JF, Kim YS, Lumbera WM, Hwang SG. Viscum Album Var Hot Water Extract Mediates Anti-cancer Effects through G1 Phase Cell Cycle Arrest in SK-Hep1 Human Hepatocarcinoma cells. Asian Pac J Cancer Prev. 2015; 16(15): 6417-21[PubMed]
  • 9. Esmaeilbeig M, Kouhpayeh SA, Amirghofran Z. An Investigation of the Growth Inhibitory Capacity of Several Medicinal Plants From Iran on Tumor Cell Lines. Iran J Cancer Prev. 2015; 8(5)[DOI][PubMed]
  • 10. Reinau D, Surber C, Jick SS, Meier CR. Nonsteroidal anti-inflammatory drugs and the risk of nonmelanoma skin cancer. Int J Cancer. 2015; 137(1): 144-53[DOI][PubMed]
  • 11. Buckman SY, Gresham A, Hale P, Hruza G, Anast J, Masferrer J, et al. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis. 1998; 19(5): 723-9[PubMed]
  • 12. Vane JR, Bakhle YS, Botting RM. Cyclooxygenases 1 and 2. Annu Rev Pharmacol Toxicol. 1998; 38: 97-120[DOI][PubMed]
  • 13. Rai N, Sarkar M, Raha S. Piroxicam, a traditional non-steroidal anti-inflammatory drug (NSAID) causes apoptosis by ROS mediated Akt activation. Pharmacol Rep. 2015; 67(6): 1215-23[DOI][PubMed]
  • 14. Rosas C, Sinning M, Ferreira A, Fuenzalida M, Lemus D. Celecoxib decreases growth and angiogenesis and promotes apoptosis in a tumor cell line resistant to chemotherapy. Biol Res. 2014; 47: 27[DOI][PubMed]
  • 15. Mohammed SI, Dhawan D, Abraham S, Snyder PW, Waters DJ, Craig BA, et al. Cyclooxygenase inhibitors in urinary bladder cancer: in vitro and in vivo effects. Mol Cancer Ther. 2006; 5(2): 329-36[DOI][PubMed]
  • 16. Chiu LC, Tong KF, Ooi VE. Cytostatic and cytotoxic effects of cyclooxygenase inhibitors and their synergy with docosahexaenoic acid on the growth of human skin melanoma A-375 cells. Biomed Pharmacother. 2005; 59 Suppl 2-7[PubMed]
  • 17. Yeh RK, Chen J, Williams JL, Baluch M, Hundley TR, Rosenbaum RE, et al. NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property? Biochem Pharmacol. 2004; 67(12): 2197-205[DOI][PubMed]
  • 18. Kim SH, Kim SH, Song YC, Song YS. Celecoxib potentiates the anticancer effect of cisplatin on vulvar cancer cells independently of cyclooxygenase. Ann N Y Acad Sci. 2009; 1171: 635-41[DOI][PubMed]
  • 19. Chattopadhyay M, Kodela R, Nath N, Dastagirzada YM, Velazquez-Martinez CA, Boring D, et al. Hydrogen sulfide-releasing NSAIDs inhibit the growth of human cancer cells: a general property and evidence of a tissue type-independent effect. Biochem Pharmacol. 2012; 83(6): 715-22[DOI][PubMed]
  • 20. Baek SJ, McEntee MF, Legendre AM. Review paper: Cancer chemopreventive compounds and canine cancer. Vet Pathol. 2009; 46(4): 576-88[DOI][PubMed]
  • 21. Pelzmann M, Thurnher D, Gedlicka C, Martinek H, Knerer B. Nimesulide and indomethacin induce apoptosis in head and neck cancer cells. J Oral Pathol Med. 2004; 33(10): 607-13[DOI][PubMed]
  • 22. Fang HM, Mei Q, Xu JM, Ma WJ. 5-aminosalicylic acid in combination with nimesulide inhibits proliferation of colon carcinoma cells in vitro. World J Gastroenterol. 2007; 13(20): 2872-7[PubMed]
  • 23. Eibl G, Reber HA, Wente MN, Hines OJ. The selective cyclooxygenase-2 inhibitor nimesulide induces apoptosis in pancreatic cancer cells independent of COX-2. Pancreas. 2003; 26(1): 33-41[PubMed]
  • 24. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods. 1983; 65(1-2): 55-63[PubMed]
  • 25. Environmental effects of ozone depletion and its interactions with climate change: progress report. 2015;
  • 26. Bishop-Bailey D, Calatayud S, Warner TD, Hla T, Mitchell JA. Prostaglandins and the regulation of tumor growth. J Environ Pathol Toxicol Oncol. 2002; 21(2): 93-101[PubMed]
  • 27. Jeong HS, Kim JH, Choi HY, Lee ER, Cho SG. Induction of cell growth arrest and apoptotic cell death in human breast cancer MCF-7 cells by the COX-1 inhibitor FR122047. Oncol Rep. 2010; 24(2): 351-6[PubMed]
  • 28. Kirschenbaum A, Klausner AP, Lee R, Unger P, Yao S, Liu XH, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology. 2000; 56(4): 671-6[PubMed]
  • 29. Sales K. J. , Katz A. A. , Howard B. , Soeters R. P. , Millar R. P. , Jabbour H. N. . Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin e receptors, and angiogenic factors by cyclooxygenase-1. Cancer Res. 2002; 62(2): 424-32
  • 30. Liu B, Qu L, Yan S. Cyclooxygenase-2 promotes tumor growth and suppresses tumor immunity. Cancer Cell Int. 2015; 15: 106[DOI][PubMed]
  • 31. Kase S, Osaki M, Honjo S, Hashimoto K, Adachi H, Tsujitani S, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in human esophageal mucosa, dysplasia and carcinoma. Pathobiology. 2004; 71(2): 84-92[DOI][PubMed]
  • 32. Rayburn ER, Ezell SJ, Zhang R. Anti-Inflammatory Agents for Cancer Therapy. Mol Cell Pharmacol. 2009; 1(1): 29-43[DOI][PubMed]
  • 33. Bichel J. Phenylbutazone (butazolidin) in the treatment of Hodgkin's disease. Acta Med Scand. 1956; 153(4): 293-8[PubMed]
  • 34. Emich R. Clinical experience with butazolidin in neoplastic processes. Wiener medizinische Wochenschrift. 1955; 105(18): 371-2
  • 35. Khan Z, Khan N, Tiwari RP, Sah NK, Prasad GB, Bisen PS. Biology of Cox-2: an application in cancer therapeutics. Curr Drug Targets. 2011; 12(7): 1082-93[PubMed]
  • 36. Hashitani S, Urade M, Nishimura N, Maeda T, Takaoka K, Noguchi K, et al. Apoptosis induction and enhancement of cytotoxicity of anticancer drugs by celecoxib, a selective cyclooxygenase-2 inhibitor, in human head and neck carcinoma cell lines. Int J Oncol. 2003; 23(3): 665-72[PubMed]
  • 37. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002; 94(4): 252-66[PubMed]
  • 38. Wang D, Dubois RN. Prostaglandins and cancer. Gut. 2006; 55(1): 115-22[DOI][PubMed]
  • 39. Tang JY, Aszterbaum M, Athar M, Barsanti F, Cappola C, Estevez N, et al. Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1+/- humans and mice. Cancer Prev Res (Phila). 2010; 3(1): 25-34[DOI][PubMed]
  • 40. Agarwal S, Achari C, Praveen D, Roy KR, Reddy GV, Reddanna P. Inhibition of 12-LOX and COX-2 reduces the proliferation of human epidermoid carcinoma cells (A431) by modulating the ERK and PI3K-Akt signalling pathways. Exp Dermatol. 2009; 18(11): 939-46[DOI][PubMed]
  • 41. Arumugam A, Weng Z, Talwelkar SS, Chaudhary SC, Kopelovich L, Elmets CA, et al. Inhibiting cycloxygenase and ornithine decarboxylase by diclofenac and alpha-difluoromethylornithine blocks cutaneous SCCs by targeting Akt-ERK axis. PLoS One. 2013; 8(11)[DOI][PubMed]
  • 42. Cheng KW, Mattheolabakis G, Wong CC, Ouyang N, Huang L, Constantinides PP, et al. Topical phospho-sulindac (OXT-328) is effective in the treatment of non-melanoma skin cancer. Int J Oncol. 2012; 41(4): 1199-203[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments